uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program

 Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~

~ Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing Technology ~

~ Large Opportunity Targeting an Estimated 1.3 million TLE Patients in the U.S. and Europe with Approximately 800,000 Drug-Resistant Patients ~

https://finance.yahoo.com/news/uniqure-acquire-corlieve-therapeutics-advance-153100215.html